Atrial fibrillation (AFib) is a leading risk factor for stroke; however, it can often go undetected. In October, the BMS-Pfizer Alliance and Fitbitannounced we are working together to help address gaps in AFib detection and accelerate diagnosis. The Alliance also announced the start of the potentially practice-changing GUARD-AF study, a randomized,controlled trial  in a real-world setting, to see if AFib screening and earlier detection and diagnosis could impact the rate of stroke, as well as bleeding leading to hospitalization, compared to usual medical care. These opportunities break new ground, demonstrating our commitment to patients and to trusted leadership in this space for years to come.